Moneyta · stock research · no sign-up needed
IONS
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue
-
Net income
-
as filed with the SEC
Institutions holding
521
+21 last quarter
Overview · IONIS PHARMACEUTICALS INC
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and fa…
Management team
- Ms. Onaiza Cadoret-Manier M.A., M.B.A., M.S. · Executive VP and Chief Global Product Strategy & Operations OfficerFind on LinkedIn
- Mr. Patrick R. O'Neil Esq. · Executive VP, Chief Legal Officer, General Counsel & Corporate SecretaryFind on LinkedIn
- Mr. D. Wade Walke Ph.D. · Senior Vice President of Investor RelationsFind on LinkedIn
- Dr. C. Frank Bennett BSc, Ph.D. · Executive VP & Chief Scientific OfficerFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
members see every cardRead the full desk report on IONS
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.